PMID- 26599807
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20191210
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 140
IP  - 7
DP  - 2016 Jul
TI  - Clinical Validation of a Novel Commercial Reverse Transcription-Quantitative 
      Polymerase Chain Reaction Screening Assay for Detection of ALK Translocations and 
      Amplifications in Non-Small Cell Lung Carcinomas.
PG  - 690-3
LID - 10.5858/arpa.2015-0419-OA [doi]
AB  - CONTEXT: -EGFR mutations and anaplastic lymphoma kinase (ALK) translocations have 
      significant biologic and therapeutic implications in lung cancers, particularly 
      lung adenocarcinomas. ALK translocations are less frequent compared with EGFR 
      mutations; interestingly, these two abnormalities are most commonly mutually 
      exclusive. The 2013 College of American Pathologists/Association for Molecular 
      Pathology/International Association for the Study of Lung Cancer molecular 
      testing guideline for lung cancers recommend a testing algorithm in which 
      detection of ALK translocations using fluorescence in situ hybridization (FISH) 
      is to be performed following testing for EGFR mutations. Such an algorithm is 
      cost-effective but potentially slows down turnaround time; and as a secondary 
      test, ALK FISH assay may not be completed because it requires the use of 
      additional tissue, and the small biopsies or cytology specimens may have been 
      exhausted in the extraction of nucleic acid for EGFR mutation screening. 
      OBJECTIVE: -To provide efficient testing of both EGFR and ALK genetic alterations 
      in small biopsies and cytology specimens. DESIGN: -We validated a highly 
      sensitive ALK reverse transcription-quantitative polymerase chain reaction 
      (RT-qPCR) assay as a screening tool for ALK translocations and amplifications. 
      RESULTS: -We performed a retrospective review of cases previously tested by FISH 
      and found that all FISH ALK translocation-positive specimens were RT-qPCR 
      positive, and all FISH ALK translocation-negative cases were RT-qPCR negative 
      (the sensitivity and specificity of the ALK RT-qPCR assay were 100%). CONCLUSION: 
      -This assay allows rapid identification of ALK alterations, can be performed in 
      conjunction with EGFR testing, and does not require use of valuable additional 
      tumor tissue.
FAU - Liu, Chunyan
AU  - Liu C
AD  - From the Department of Pathology and Genomic Medicine, Houston Methodist 
      Hospital, Houston, Texas. Dr Portier is now with Roche Tissue Diagnostics/Ventana 
      Medical Systems (ROCHE Group), Tucson, Arizona.
FAU - Pepper, Kristi
AU  - Pepper K
FAU - Hendrickson, Heather
AU  - Hendrickson H
FAU - Cagle, Philip T
AU  - Cagle PT
FAU - Portier, Bryce P
AU  - Portier BP
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20151124
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/pathology
MH  - Cell Line, Tumor
MH  - ErbB Receptors/genetics
MH  - *Gene Amplification
MH  - Humans
MH  - Lung Neoplasms/*genetics/pathology
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/*methods
MH  - *Translocation, Genetic
EDAT- 2015/11/26 06:00
MHDA- 2017/02/24 06:00
CRDT- 2015/11/25 06:00
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
AID - 10.5858/arpa.2015-0419-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2016 Jul;140(7):690-3. doi: 10.5858/arpa.2015-0419-OA. Epub 
      2015 Nov 24.